Phase 4
Completed N=36
Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
Source: ClinicalTrials.gov NCT00946296 ↗Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Dec 2015
Primary outcomePrimary: Blood Loss During Surgery — 61.67; 161.67 mL
Summary
The purpose of this study is to determine whether a brief course of SSKI (saturated solution of potassium iodide) administered preoperatively provides any benefit in the surgical management of patients undergoing thyroidectomy as definitive management of their Graves Disease.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Blood Loss During Surgery |
61.67; 161.67 | — |
Eligibility Criteria
Inclusion Criteria
- Adult patients with a clinical diagnosis of Graves Disease
- Patients who have selected surgical resection as treatment of their Graves Disease
- Prior use of anti thyroid medication so that patient is clinically and biochemically euthyroid
Exclusion Criteria
- Patients deemed unfit for surgery by operating surgeon or anesthesist
- Patients who are clinically hyperthyroid or have T3 or T4 levels 2X the upper limit of normal
Data sourced from ClinicalTrials.gov (NCT00946296). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.